Covalent binding of phenytoin to protein and modulation of phenytoin metabolism by thiols in A/J mouse liver microsomes

D Roy and WR Snodgrass

Department of Pharmacology-Toxicology, University of Texas Medical Branch, Galveston.

The role of thiols (nonprotein and protein) in the metabolic activation of phenytoin was examined. In vitro phenytoin covalent binding and metabolite formation were determined in hepatic microsomes from A/J mice. Covalent binding of a phenytoin-reactive intermediate to microsomal protein was linear with respect to time, protein concentration and phenytoin concentration. Covalent binding was inhibited by inhibitors of cytochrome P-450. Inducers of cytochrome P- 450 enhanced phenytoin covalent binding as follows: phenobarbital greater than 3-methylcholanthrene greater than saline-treated controls. Low molecular weight thiols (GSH, cysteine and cysteamine), a thiol generator (methylthiazolidine carboxylate), and thiol modifying agents (N-ethylmaleimide, mercuric chloride and diamide) significantly inhibited covalent binding. Amino acids other than cysteine did not decrease the covalent binding. Formation of the metabolites, para- hydroxyphenytoin and phenytoin dihydrodiol, was greater following preincubation with GSH or cysteine. In summary, protein thiol groups appear to be important sites for in vitro covalent binding of a reactive intermediate of phenytoin. These data suggest glutathione may protect membrane-bound enzymes responsible for phenytoin metabolism from attack by an electrophilic or free radical reactive intermediate of phenytoin and GSH may inactivate a phenytoin-reactive metabolite by formation of a putative glutathione conjugate.

Volume 252, Issue 3, pp. 895-900, 03/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				D. Lin, M J. Tucker, and M. J Rieder Increased Adverse Drug Reactions to Antimicrobials and Anticonvulsants in Patients with HIV Infection Ann. Pharmacother., September 1, 2006; 40(9): 1594 - 1601. [Abstract] [Full Text] [PDF]

				C. K. Svensson, E. W. Cowen, and A. A. Gaspari Cutaneous Drug Reactions Pharmacol. Rev., September 1, 2001; 53(3): 357 - 379. [Abstract] [Full Text] [PDF]

				H. Yamazaki, T. Komatsu, K. Takemoto, M. Saeki, Y. Minami, Y. Kawaguchi, N. Shimada, M. Nakajima, and T. Yokoi Decreases in Phenytoin Hydroxylation Activities Catalyzed by Liver Microsomal Cytochrome P450 Enzymes in Phenytoin-Treated Rats Drug Metab. Dispos., April 1, 2001; 29(4): 427 - 434. [Abstract] [Full Text]

				E. P. Gallagher and K. M. Sheehy Effects of Phenytoin on Glutathione Status and Oxidative Stress Biomarker Gene mRNA Levels in Cultured Precision Human Liver Slices Toxicol. Sci., January 1, 2001; 59(1): 118 - 126. [Abstract] [Full Text] [PDF]

				T. Komatsu, H. Yamazaki, S. Asahi, E. M. J. Gillam, F. P. Guengerich, M. Nakajima, and T. Yokoi Formation of A Dihydroxy Metabolite of Phenytoin in Human Liver Microsomes/cytosol: Roles of Cytochromes P450 2c9, 2c19, and 3a4 Drug Metab. Dispos., November 1, 2000; 28(11): 1361 - 1368. [Abstract] [Full Text]